摘要
目的评价放疗联合表皮生长因子受体-酪氨酸激酶抑制剂（EGFR．TKI）靶向治疗Ⅳ期非小细胞肺癌（NSCLC）的疗效及安全性。方法26例NSCLC患者，其中骨转移16例，脑转移10例。放疗部位包括肺原发灶及骨、脑转移灶，放疗期间同时服用吉非替尼250mg每天1次，或厄洛替尼150mg每天1次，直至肿瘤进展或出现不可耐受的副作用。结果所有患者在放疗期间均能完成放疗联合靶向治疗，12例患者出现腹泻，8例伴发呕吐，12例合并有皮疹。放疗前按美国东部肿瘤协作组（ECOG）评分平均为3分，放疗后为2分。骨转移局部控制率为93．8％（15／16），脑转移灶控制率为70．0％（7／10），肺部6个月局部控制率为84．6％（22／26）。结论针对Ⅳ期NSCLC，姑息性放疗联合靶向治疗是有效而安全的治疗方法，其对生存时间的影响需要进一步观察。
Objective To evaluate the efficacy and safety of radiation combined with targeted therapy of EGFR-TKI in the patients with stage IV non-small cell lung cancer （NSCLC）. Methods There were 17 female and 9 male patients with NSCLC enrolled into this study, which included 19 adenocarcinoma, 4 alveolar carcinoma and 3 uncertain carcinoma according to the iconography findings. Sixteen patients suffered from single or multiple bone metastasis, and 10 eases with brain metastasis. Gefitinib 250 mg or Erlotinib 150 mg per day were administrated during and after the process of radiation until the disease progressed. Results All patients had complete combined therapy, 12 of them suffered from diarrhea, 8 from emesia and 12 from erythra. The average score of ECOG improved from 3 to 2 after combined therapy. The bone metastasis control rate was 93.8% ,brain metastasis control rate was 70.0%, and the 6-month local lung lumps control rate was 84.6%. Conclusion Palliative radiation combined with targeted therapy of EGFR-TKI is an effect and safe therapy for the patients with the stage IV of NSCLC,but the influence on survival shall be observed in further study.
出处
《中国综合临床》
2011年第7期744-746,共3页
Clinical Medicine of China
